Sera Prognostics (NASDAQ:SERA – Get Rating) is one of 45 public companies in the “Medical laboratories” industry, but how does it contrast to its rivals? We will compare Sera Prognostics to related companies based on the strength of its risk, dividends, earnings, valuation, institutional ownership, analyst recommendations and profitability.
This is a summary of recent ratings and price targets for Sera Prognostics and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Sera Prognostics Competitors||353||1096||1762||47||2.46|
Valuation & Earnings
This table compares Sera Prognostics and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Sera Prognostics||$80,000.00||-$35.01 million||-0.34|
|Sera Prognostics Competitors||$1.09 billion||$56.91 million||8.01|
Sera Prognostics’ rivals have higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
63.2% of Sera Prognostics shares are owned by institutional investors. Comparatively, 61.5% of shares of all “Medical laboratories” companies are owned by institutional investors. 20.1% of shares of all “Medical laboratories” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This table compares Sera Prognostics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Sera Prognostics Competitors||-1,687.27%||-37.96%||-17.61%|
Sera Prognostics rivals beat Sera Prognostics on 8 of the 12 factors compared.
Sera Prognostics Company Profile (Get Rating)
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with MarketBeat.com's FREE daily email newsletter.